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Abstract: Background and Objectives: Atrial fibrillation (AF) is associated with increased mortality,
predictors of which are poorly characterized. We investigated the predictive power of the
commonly used CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥ 75 years
[doubled], diabetes, stroke/transient ischemic attack/thromboembolism [doubled], vascular disease
[prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65–75 years, sex category
[female]), the HAS-BLED score (hypertension, abnormal renal/liver function, stroke, bleeding history
or predisposition, labile international normalized ratio [INR], elderly [age ≥ 65 years], drugs/alcohol
concomitantly), and their combination for mortality in AF patients. Methods: The PREvention oF
thromboembolic events—European Registry in Atrial Fibrillation (PREFER in AF) was a prospective
registry including AF patients across seven European countries. We used logistic regression to analyze
the relationship between the CHA2DS2-VASc and HAS-BLED scores and outcomes, including mortality,
at one year. We evaluated the performance of logistic regression models by discrimination measures
(C-index and DeLong test) and calibration measures (Hosmer and Lemeshow goodness-of-fit and
integrated discrimination improvement (IDI), with bootstrap techniques for internal validation. Results:
In 5209 AF patients with complete information on both scores, average one-year mortality was
3.1%. We found strong gradients between stroke/systemic embolic events (SSE), major bleeding
and—specifically—mortality for both CHA2DS2-VASc and HAS-BLED scores, with a similar C-statistic
for event prediction. The predictive power of the models with both scores combined, removing
overlapping components, was significantly enhanced (p < 0.01) compared to models including
either CHA2DS2-VASc or HAS-BLED alone: for mortality, C-statistic: 0.740, compared to 0.707 for
CHA2DS2-VASc or 0.646 for HAS-BLED alone. IDI analyses supported the significant improvement for
the combined score model compared to separate score models for all outcomes. Conclusions: Both
the CHA2DS2-VASc and the HAS-BLED scores predict mortality similarly in patients with AF, and a
combination of their components increases prediction significantly. Such combination may be useful
for investigational and—possibly—also clinical purposes.
J. Clin. Med. 2020, 9, 3987; doi:10.3390/jcm9123987 www.mdpi.com/journal/jcm
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1. Introduction
Atrial fibrillation (AF) is common, and is associated not only with high incidences of stroke,
thromboembolism and disabilities, but also with significant mortality [1,2]. Treatment guidelines
recommend considering both thromboembolic and bleeding risks when prescribing anticoagulation
for stroke prevention in AF [1,2]. The CHA2DS2-VASc score (congestive heart failure, hypertension,
age ≥ 75 years [doubled], diabetes, stroke/transient ischemic attack/thromboembolism [doubled],
vascular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque],
age 65–75 years, sex category [female]) has been developed as a clinical risk score in patients
with AF to predict the risk of stroke [3], and is now adopted in most widely used guidelines to assess
such risk [1,2]. In some studies, the CHA2DS2-VASc score has also been used beyond its original
purpose and disease populations. The score has been shown to predict outcomes broader than ischemic
stroke, for instance thromboembolic events and death, in non-AF patient populations, such as patients
with ischemic heart disease [4], diabetes [5], heart failure [6], in non-AF community patients [7], or in
unselected patients [8]. The HAS-BLED score (hypertension, abnormal renal/liver function, stroke,
bleeding history or predisposition, labile international normalized ratio [INR], elderly [age ≥ 65 years],
drugs/alcohol concomitantly) was developed to predict bleeding amongst AF patients [9]. It is still
widely used, although now de-emphasized due the lesser relevance of bleeding considerations in
isolation to determine therapy for AF [1,2].
Due to the overlapping risk factors between CHA2DS2-VASc and HAS-BLED scores, both appear
to predict adverse events of any kind. The compared performances of the two scores and their potential
combination for the prediction of mortality have not been previously evaluated, and might be of
interest due to the wide adoption of these scores. The aim of the current study was to investigate such
predictive power in patients with AF.
2. Methods
Individual patient data were pooled from the PREvention oF thromboembolic events—European
Registry in Atrial Fibrillation (PREFER in AF), a prospective registry of 7243 AF patients from
461 hospitals and 7 European countries (Austria, France, Germany, Italy, Spain, Switzerland, and
the United Kingdom) conducted between January 2012 and January 2013, with 1-year follow-up.
Details of the PREFER in AF Registry, including main findings at enrolment and definitions used, have
been published [10]. For the purpose of this study, we focused on the following outcomes: ischemic
stroke and or systemic embolic events (SEE), major bleeding and all-cause mortality.
2.1. Registry Data and Patients’ Population
Patients were included in the PREFER in AF registry if they were at least 18 years of age, gave written
informed consent for participation, and had a history of AF documented by electrocardiography
or by an implanted pacemaker or defibrillator within the preceding 12 months. Patients were
consecutively enrolled with no explicit exclusion criteria in order to avoid selection biases. Patients’
characteristics, including demographic and clinical data, information on risk factors and treatment
strategies, were collected at baseline and entered into an electronic case-report form with on-site
verification of source data in approximately 5% of the sites. The study management was overseen
by a scientific Steering Committee, as published [10]. Baseline data were collected between January
2012 and January 2013. A total of 7243 patients were enrolled in 461 centers from seven European
countries (Austria, France, Germany, Italy, Spain, Switzerland, and the U.K.). For regional comparisons,
Austria, Switzerland, and Germany were combined into one pre-specified region labelled “DACH”.
Forty-two percent of enrolling physicians were office-based, and 53% were hospital-based; 89% were
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cardiologists. After baseline inclusion, patients were followed-up for one year, recording information
on clinical events, clinical characteristics, patterns of prescriptions and patients’ adherence to guidelines,
quality of life and treatment satisfaction.
One year after the baseline enrolment, patients underwent a follow-up visit (12 ± 2 months after
baseline visit). As for the baseline visit, all data were captured through an electronic case report form
(eCRF) including a wide range of plausibility checks for the entered variables. In addition, on-site
source data verification was performed in approximately 5% of the sites. The study management was
executed through a contract research organization (SSS International Clinical Research GmbH, Munich,
Germany). The study management was overseen by a scientific steering committee. Considered
variables were the same as the enrollment visit, including demographic data, data about AF incidence
and type, heart rate and symptoms, risk factors and comorbidities, thromboembolic risk evaluated by
CHADS2 and CHA2DS2-VASc score, bleeding risk from the HAS-BLED score, history of significant
clinical events and hospitalizations, treatment for AF, and anticoagulation quality evaluated by the last
3 INR values prior to follow-up visit.
Patients who completed both CHA2DS2-VASc and HAS-BLED risk scores at baseline and at the
one-year follow-up were included in the current study. The CHA2DS2-VASc score ranges between
0 and 9, with a higher score indicating a higher risk of stroke. HAS-BLED also ranges between 0
and 9, with a higher score indicating a higher risk of bleeding. For the purpose of this analysis,
the CHA2DS2-VASc and HAS-BLED risk scores at study entry were used. For the analysis of their
combination, overlapping components were used only once. Because of some differences in the
definition of hypertension (blood pressure consistently above 140/90 mmHg or treated hypertension
on medication in the CHA2DS2-VASc score [3]; uncontrolled, >160 mmHg systolic in the HAS-BLED
score [9]), the more inclusive definition of hypertension in the CHA2DS2-VASc score was retained
for the combination score, in this case therefore ranging between 0 and 12. Sensitivity analyses were
conducted to assess whether medication type had an effect on the model performance.
2.2. Outcomes
The combined endpoint of ischemic stroke and/or SEE was defined as ischemic stroke, transient
ischemic attack (TIA) (“a small ischemic stroke”), arterial embolism, venous thromboembolic event,
or pulmonary thromboembolism event during the follow-up. Major bleeding was defined, according
to the definition of the International Society on Thrombosis and Haemostasis (ISTH), as gastrointestinal
bleeding, intracerebral bleeding, or other life-threatening or major bleeding occurring during the
follow-up [11]. Estimates of death rates relied on spontaneous reporting. Data were extracted from
the comments section of the electronic case-report form and then verified with each site to gain more
information about their validity.
2.3. Statistical Methods
Descriptive statistics are presented here as frequencies and percentages (n, %) for categorical
variables, and as means and standard deviations (SDs) for continuous variables. The difference
in baseline characteristics between the study sample and non-study sample were tested, using the
Chi-squared test, the rank sum test, or the t-test as appropriate.
Logistic regression was used to separately analyze the relationships between the three outcome
events (i.e., stroke/SSE, major bleeding and mortality) and the CHA2DS2-VASc and HAS-BLED scores.
For each outcome, five analyses were conducted, evaluating different sets of explanatory variables.
The first two analyses evaluated the predictive power of the CHA2DS2-VASc scores. One analysis
included the total risk score as a continuous explanatory variable (ranging from 0 to 9), while the
second analysis evaluated the individual items of the CHA2DS2-VASc score [3] as explanatory variables,
which were treated as dichotomous variables [i.e., congestive heart failure (or left ventricular systolic
dysfunction), hypertension: blood pressure consistently above 140/90 mmHg (or treated hypertension
on medication), age: ≥75 years, age 65–74 years, diabetes mellitus, prior stroke or transient ischemic
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attack or thromboembolism, vascular disease (i.e., peripheral artery disease, myocardial infarction,
aortic plaque), female sex]. The third and fourth analyses considered the HAS-BLED score [9], with one
analysis including the total risk score only as a continuous exploratory variable (ranging from 0–9),
and a second analysis considering individual components of the HAS-BLED scores [9] as dichotomous
variables (i.e., hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition,
labile international normalized ratio, age ≥ 65 years, drugs/alcohol concomitantly). For the final
analysis, the combination of individual items of the CHA2DS2-VASc and HAS-BLED scores were
used as explanatory variables (dichotomously) rather than a combination of the total score, excluding
double reporting of overlapping risk items. The confidence intervals of the coefficients for each logistic
regression model were corrected for bias and skewness in the distribution of the bootstrap estimates,
for which the average was taken over 100 repetitions, obtained by bootstrap with resampling.
The performance of each model was evaluated by discrimination and calibration [12]. To evaluate
discrimination, we used the C-index (area under the curve, AUC) using bootstrap to obtain
bias-corrected standard errors, after which the null-hypothesis of no differences between the C-indexes
of the models was tested using the Wald test. In addition, we evaluated the integrated discrimination
improvement (IDI) [13]. We assessed calibration, referring to the agreement between observed number
of events and predicted probability of the occurrence of these events [14], using the Hosmer and
Lemeshow goodness-of-fit test.
We performed all analyses with the STATA statistical software (StataCorp. 2017. Release 15.
College Station, TX, USA).
3. Results
3.1. Patient Characteristics
In the original PREFER in AF population, of the 7243 patients, age (mean ± SD) was
71.5 ± 11 years, 60.1% were male, and the CHA2DS2VASc score was 3.4 ± 1.8. Thirty percent
of the patients had paroxysmal, 24.0% persistent, 7.2% long-standing persistent, and 38.8% permanent
AF. Oral anticoagulation (OAC) was used in most patients: 4799 patients (66.3%) received a vitamin
K antagonist (VKA) as mono-therapy, 720 patients (9.9%) a combination of VKA and antiplatelet
agents (AP), and 442 patients (6.1%) received a new oral anticoagulant drugs (NOAC). AP alone
was given in 808 patients (11.2%) and there was no antithrombotic therapy in 474 patients (6.5%).
Amongst 5209 patients who had complete information for both the CHA2DS2VASc and HAS-BLED
scores at baseline, the mean age was 71.8 ± 10.5 years; 3145 subjects (60.4%) were male. This subsample
of 5209 patients was representative of the whole sample population published in the registry [10]
across a wide spectrum of baseline variables, including comorbidities. Patients’ characteristics at
baseline are shown in Table 1. Stroke risk was high (mean CHA2DS2VASc total score of 3.4 ± 1.8),
with a total score ranging between 2 and 5 in the majority of patients (>70%). Bleeding risk had a total
score ranging from 1 to 3 in >80% of cases, and a mean HAS-BLED total score of 2.0 ± 1.1. There was
a different representation of the type of AF: permanent AF was found more frequently, accounting
for 2070 patients (40%); long-standing persistent AF was the least represented category, with only
391 patients (7.52%); and paroxysmal and persistent AF accounted for 1499 and 1239 patients (29%
vs. 24%), respectively. In terms of treatment, the majority of patients (3548, 68%) were on treatment
with a vitamin K antagonist (VKA) at baseline, and with a small number (305 patients, 6%) taking a
non-vitamin K antagonist oral anticoagulant (NOAC).
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Table 1. Patients’ characteristics at baseline.
n %
Patients 5209 100.0
Age, mean (SD) 71.76








Primary school 2500 48.0
Secondary school 1651 31.7






















VKA + Antiplatelet 306 5.9



























Congestive heart failure 1546 29.7
Hypertension 3726 71.5
Diabetes mellitus 1181 22.7
Stroke/TIA 832 16.0
Vascular disease 1177 22.6
Renal function 696 13.4
Liver function 103 2.0
Stroke 475 9.1
Bleeding 244 4.7
Labile INR 692 13.3
Drug 1387 26.6
Alcohol 130 2.5
Abbreviations: SD = standard deviation; DACH = Germany, Austria, and Switzerland; AF = atrial fibrillation;
NOAC = non-vitamin K antagonist oral anticoagulant; VKA = vitamin K antagonist; CHA2DS2-VASc = congestive
heart failure, hypertension, age 75 years [doubled], diabetes, stroke/transient ischemic attack/thromboembolism
[doubled], vascular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65–75
years, sex category [female]; HAS-BLED = hypertension, abnormal renal/liver function, stroke, bleeding history or
predisposition, labile international normalized ratio [INR], elderly [age ≥ 65 years], drugs/alcohol concomitantly;
TIA = transient ischemic attack.
The majority of the non-study sample (n = 2034 patients, excluded when no risk scores were
available) had similar baseline characteristics as patients included in the study sample, with the
exception of chronic kidney disease (CKD), AF type at baseline, treatment with NOAC/VKA/antiplatelet
agents, and age. CKD was more prevalent in the study sample compared to the non-study sample
(study vs. non-study sample: 13.8% vs. 11.2%), while paroxysmal AF was more prevalent in the
non-study sample (study vs. non-study sample: 28.8% vs. 33.0%). Patients were older in the study
sample (study vs. non-study sample: 71.8 vs. 70.7 years). Finally, baseline treatment of VKA was more
prevalent in the study sample, while NOAC and antiplatelet baseline treatment were more prevalent
in the non-study sample.
3.2. Outcome Distributions
Rates of stroke/SEE and major bleeding at the one-year follow-up were 2.3% (122 patients) and
2.9% (149 patients), respectively. At one year, 3.1% of patients died (160 out of 5209). The percentage of
patients with the examined outcomes (i.e., stroke/SSE, major bleeding, and death) in each risk score
category of CHA2DS2VASc and HAS-BLED, respectively, are shown in Figures 1 and 2. There was a
strong gradient between the outcome frequency and risk scores: overall, higher risk scores were both
positively correlated with the occurred outcomes. However, there were very few events in the highest
score category, with only 10 patients having a CHA2DS2-VASc total score of 9, and only 2 patients with
a HAS-BLED total score of 7 (none reported a HAS-BLED total score of 8 or 9).
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Figure 1. Outcomes (stroke/systemic embolic events (SSE), bleeding and mortality) by CHA2DS2-VASc
risk score in the present study.
Figure 2. Outcomes (stroke/systemic embolic events (SSE), bleeding and mortality) by HAS-BLED risk
score in the present study.
3.3. Logistic Regression Analysis Results
3.3.1. CHA2DS2-VASc Risk Score
The predictive values of the CHA2DS2-VASc risk score for each outcome event are shown in
Table S1.
Amongst the models including only the total risk score of CHA2DS2-VASc as an explanatory
variable, only the model predicting major bleeding had a good fit (p-value > 0.05), as indicated by
the Hosmer–Lemeshow goodness-of-fit test (p = 0.014, 0.269 and 0.039 for stroke/SSE, major bleeding,
and mortality, respectively). As suggested by the C-statistic, the predictive ability was highest for the
model predicting stroke/SSE (0.584; 95% CI 0.536–0.637), followed by the model predicting mortality
(0.559; 95% 0.513–0.604) and the model predicting major bleeding (0.520; 95% CI 0.478–0.567).
The models with individual components of the CHA2DS2VASc risk score presented a better fit
according to the Hosmer–Lemeshow goodness-of-fit test (with the exception of the model predicting
mortality) and an improved predictive ability compared to the model based on the total score alone.
Components of the scores assessed here and showing a statistically significant coefficient were different
across models predicting different outcomes. For instance, for predicting mortality, congestive heart
failure, hypertension, age >75 years, and diabetes mellitus were statistically significant, whereas
in predicting stroke/SSE, only the terms congestive heart failure and stroke/TIA had a statistically
significant coefficient.
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3.3.2. HAS-BLED Risk Score
For the models including only the total risk score of HAS-BLED as an explanatory variable,
all models had a good fit (p-value > 0.05), as indicated by the Hosmer–Lemeshow goodness-of-fit test
(p = 0.432, 0.594 and 0.250 for stroke/SSE, major bleeding, and mortality, respectively). Evaluating the
models with individual components, the Hosmer–Lemeshow goodness-of-fit test indicated a good fit
for all models as well (Table S2). The models with individual components were all compared to models
with total scores (C-statistics were significantly improved, p < 0.05 for all models). However, items with
statistically significant coefficients varied depending on the outcome of interest; for instance, history of
bleeding was statistically significant for predicting major bleeding but was not statistically significant
for predicting mortality or stroke/SSE (Table S2).
3.3.3. CHA2DS2-VASc and HAS-BLED Combined
Combining the individual components of the CHA2DS2VASc and HAS-BLED risk scores with the
exclusion of duplicated items generated the most favorable predictive results. All models had a good
fit, indicated by the lowest value of the Hosmer goodness-of-fit test (p-value > 0.05) with a C-statistic
of 0.731 (95% CI 0.681–0.778), 0.702 (95% CI 0.659–0.747) and 0.740 (95% CI 0.699–0.780) for stroke/SSE,
major bleeding, and mortality, respectively (Table 2). For predicting stroke/SSE, statistically significant
items included congestive heart failure, stroke/TIA, abnormal liver function, labile INR, and drugs;
for predicting major bleeding, statistically significant items included age >75 years, vascular disease,
abnormal renal and liver function, bleeding and alcohol consumption; and for predicting mortality,
statistically significant items included congestive heart failure, hypertension, age >75 years, abnormal
renal and liver function.
The predictive performance of the models combining the CHA2DS2VASc and HAS-BLED
components compared to the CHA2DS2-VASc individual component models alone was enhanced for
the prediction of all outcomes (Table 3 and Figure 3). For mortality, the C-statistic showed a significant
improvement (0.707 vs. 0.740, p = 0.005). Although the improvement in sensitivity was small, it was
significant (IDI: 1.79%; p < 0.001). Similar results were demonstrated in models predicting stroke and
major bleeding, with the largest improvements demonstrated in the model predicting stroke/SSE.
Figure 3. C-index of logistic models by outcome and predictor items risk scores; * denotes a C-index of
the specific score significantly different (p-value < 0.05) from C-index of the combined score.
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Table 2. Logit regression results with CHA2DS2-VASc and HAS-BLED combined.
Coefficient p-Value Bias 95% CI (Bias-Corrected) Log-Likelihood Homes-LEWESHOW C-Statistic 95% CI (Bias-Corrected)
−522.351 1.000 0.731 0.681 0.778
Stroke/Systemic
Embolic Events
Congestive heart failure 0.643 0.002 0.015 0.234 1.038
Hypertension −0.082 0.714 −0.016 −0.467 0.362
Age >75 years 0.534 0.089 0.023 −0.059 1.190
Diabetes mellitus 0.053 0.811 −0.026 −0.403 0.446
Stroke/transient ischemic
attack
1.017 0.000 0.011 0.625 1.308
Vascular disease −0.344 0.144 0.017 −0.840 0.071
Age 65 to 74 years 0.037 0.917 0.022 −0.634 0.576
Sex category 0.283 0.218 0.003 −0.231 0.648
Abnormal renal function −0.193 0.522 −0.016 −0.926 0.327
Abnormal liver function 1.014 0.010 −0.041 0.087 1.686
Bleeding 0.375 0.345 −0.117 −0.282 1.019
Labile INR 0.920 0.000 −0.004 0.460 1.237
Drug 0.872 0.000 −0.024 0.494 1.312
Alcohol 0.690 0.183 −0.020 −0.502 1.551
Constant −5.079 0.000 −0.059 −5.740 −4.328
Major bleeding −628.686 0.999 0.702 0.659 0.747
Congestive heart failure −0.138 0.487 −0.005 −0.581 0.221
Hypertension 0.030 0.887 0.011 −0.353 0.472
Age >75 years 0.661 0.015 0.035 0.066 1.119
Diabetes mellitus −0.134 0.498 −0.037 −0.579 0.216
Stroke/transient ischemic
attack
−0.136 0.582 0.022 −0.546 0.388
Vascular disease 0.637 0.001 −0.015 0.299 1.069
Age 65 to 74 years −0.107 0.708 0.020 −0.618 0.368
Sex category 0.035 0.868 −0.016 −0.305 0.453
Abnormal renal function 0.541 0.006 0.032 0.264 1.002
Abnormal liver function 0.890 0.022 −0.045 −0.005 1.654
Bleeding 1.425 0.000 0.018 0.947 1.804
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Table 2. Cont.
Coefficient p-Value Bias 95% CI (Bias-Corrected) Log-Likelihood Homes-LEWESHOW C-Statistic 95% CI (Bias-Corrected)
Labile INR 0.417 0.059 0.007 0.119 0.937
Drug 0.219 0.263 −0.013 −0.043 0.677
Alcohol 0.904 0.023 −0.077 0.174 1.527
Constant −4.428 0.000 −0.061 −4.976 −3.905
Mortality −649.047 0.233 0.740 0.699 0.780
Congestive heart failure 0.802 0.000 0.001 0.365 1.075
Hypertension −0.453 0.013 0.015 −0.811 −0.129
Age >75 years 1.051 0.000 0.032 0.460 1.476
Diabetes mellitus 0.246 0.222 −0.022 −0.119 0.684
Stroke/transient ischemic
attack
0.070 0.743 0.018 −0.432 0.399
Vascular disease 0.082 0.705 −0.028 −0.335 0.459
Age 65 to 74 years 0.229 0.522 0.041 −0.627 0.825
Sex category 0.010 0.958 −0.032 −0.365 0.333
Abnormal renal function 0.969 0.000 0.032 0.481 1.269
Abnormal liver function 1.003 0.001 −0.032 0.399 1.602
Bleeding 0.420 0.152 −0.047 −0.229 0.829
Labile INR 0.111 0.661 −0.009 −0.411 0.539
Drug 0.259 0.178 0.003 −0.080 0.593
Alcohol 0.126 0.812 −0.120 −0.918 0.945
Constant −4.625 0.000 −0.061 −5.200 −4.130
Abbreviations: CHA2DS2-VASc = congestive heart failure, hypertension, age ≥75 years [doubled], diabetes, stroke/transient ischemic attack/thromboembolism [doubled], vascular disease
[prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65–74 years, sex category [female]; HAS-BLED = hypertension, abnormal renal/liver function, stroke, bleeding
history or predisposition, labile international normalized ratio [INR], elderly [age ≥65 years], drugs/alcohol concomitantly.
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Table 3. Evaluation of the predictive ability of the prediction models for the detection of stroke/SSE,
major bleeding and mortality using C-index and integrated discrimination improvement indices.
Outcome C-Statistic 95% CI (Bias-Corrected) p-Value IDI, % p-Value
Stroke/SSE




0.731 0.681 0.778 0.010 3.11 0.000




0.731 0.681 0.778 0.001 1.46 0.000
Major
bleeding




0.702 0.659 0.747 0.000




0.702 0.659 0.747 0.002
Mortality




0.740 0.700 0.779 0.005 1.79 0.000




0.740 0.700 0.779 0.000 1.26 0.000
Abbreviations: SSE: Systemic Embolic Events; REF; reference model; IDI, integrated discriminating improvement
index; CHA2DS2-VASc=congestive heart failure, hypertension, age ≥75 years [doubled], diabetes, stroke/transient
ischemic attack/thromboembolism [doubled], vascular disease [prior myocardial infarction, peripheral artery disease,
or aortic plaque], age 65–74 years, sex category [female]; HAS-BLED=hypertension, abnormal renal/liver function,
stroke, bleeding history or predisposition, labile international normalized ratio [INR], elderly [age ≥65 years],
drugs/alcohol concomitantly.
The improvement of the models with the CHA2DS2VASc and HAS-BLED combined components
over the HAS-BLED individual component models alone was significant in all models in terms of
C-statistic and IDI (Table 3 and Figure 3). Moreover, we found small but significant improvement in
sensitivity for all outcomes
We found no heterogeneity in analyzing data restricted to patients on NOACs (Table S3).
Details on the analyses broken down for AF type (paroxysmal, persistent, long-standing persistent,
permanent) are reported in Table S4. We found numerical improvements of the C-statistic in all types of
AF, although the achievement of statistically significant improvements was limited by the limitations
of sample sizes.
4. Discussion
This study has three new major interesting findings: 1. Mortality was higher than the occurrence
of stroke/SSE in the patient population of this nearly-contemporary registry with mostly anticoagulated
AF patients; 2. Both the CHA2DS2VASc and the HAS-BLED risk scores were reasonably good predictors
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of stroke/SSE and major bleeding, but they were also good predictors of mortality; 3. A combination of
items included in the two scores significantly improved prediction of death. These results may have
practical implications for the prediction of adverse events in patients with AF.
AF is the most common type of heart rhythm disorder and is associated with a 1.5- to
1.9-fold higher risk of death in part due to the strong association with thromboembolic events.
Since data from the Framingham heart study, AF has been known to be an independent risk
factor for stroke [15]: therefore a major management decision in AF is determining the risk of
stroke and appropriate antithrombotic treatment weighted against the risk of serious bleeding.
The CHA2DS2-VASc and HAS-BLED risk scores are the most widely used algorithms to determine the
yearly thromboembolic risk and to predict bleeding [16]. They were developed to predict stroke/SSE
and bleeding in non-anticoagulated patients, and not developed to predict mortality, which is yet a
numerically relevant endpoint in AF even when the risk of stroke/SSE is abated by anticoagulation.
Determining, therefore, the comparative performances of these scores in anticoagulated patients not
only for stroke/SSE and bleeding, but also for mortality, is new and medically relevant.
4.1. Previous Study Comparisons: Scores for Stroke vs. Scores for Bleeding
Previous data from the AMADEUS trial data base in AF patients anticoagulated with
either idraparinux or VKAs demonstrated that the CHADS2 and CHA2DS2-VASc scores
(used for stroke risk assessment) could be used to predict serious bleeding, comparing against
a score—HAS-BLED—intended for bleeding assessment [17]. In a subsequent comparison of
stroke risk scores (CHADS2 and CHA2DS2-VASc) and three bleeding risk scores [HAS-BLED,
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT), and AnTicoagulation
and Risk factors In Atrial fibrillation (ATRIA)] from a large administrative database of NOAC-treated
patients in routine clinical practice, CHADS2, CHA2DS2-VASc, HAS-BLED, ORBIT and ATRIA scores
had similar performances in predicting major bleeding, highlighting that patients at a high risk of stroke
are also at high risk of bleeding [18]. Thus, previous data concur with the present findings, indicating
that current risk scores, also because of overlapping components, do not have a high discriminating
capacity for stroke/SSE vs. bleeding events.
4.2. Previous Studies for Mortality Prediction in Atrial Fibrillation
We carried out a comprehensive literature search to investigate published articles regarding the
prediction of death through clinical scores derived for AF. We retrieved 25 published articles referring
to mortality prediction (Table S5), Whenever in AF, all these studies referred to anticoagulated patients,
a setting different from the original one used to derive the CHA2DS2-VASc score [3]. In several
instances, causes of death in AF appeared unrelated to thromboembolism or bleeding. For example,
in anticoagulated AF patients with a median CHA2DS2-VASc score of 4, Gallego et al. showed that more
deaths (4.5/100 patient-years) occurred for causes other than a thromboembolic (only 1.3 patient-years)
or a hemorrhagic event (0.4 patient-years). Here, the HAS-BLED score, besides bleeding, predicted
adverse events, including all-cause and cardiovascular mortality [19].
Several studies out of AF have shown that scores such as HAS-BLED [20] and
CHA2DS2-VASc [4,5,21–23] predict adverse events other than stroke and bleeding, including death.
Some previous studies, such as the one from the GARFIELD-AF registry [24], have reported a better
prediction of events than the two above scores. Previous literature converges in demonstrating death as
a numerically frequent outcome in anticoagulated AF patients, more than thromboembolic or bleeding
events; and that scores are general markers of risk, including the risk of death. No previous report,
however, has addressed the possibility of predicting risk through a combination of CHA2DS2-VASc and
HAS-BLED. This would have medical relevance due to the current widespread adoption of these scores.
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4.3. Added Value of the Present Study from the PREFER in AF Registry
The PREFER in AF registry informed on AF patient profiles in a real-world clinical context,
helping to identify specific at-risk patient groups, including those with comorbidities that predispose
them to thrombotic events. The current study deriving from that registry is the first that compares
and combines a stroke risk score with a bleeding score in order to give the best predictive value on
mortality. In line with previously published studies, our report shows strong gradients between the
CHA2DS2-VASc and the HAS-BLED risk scores and outcomes examined (stroke/SSE, major bleeding
and death). Here, the CHA2DS2-VASc score predicts mortality, in addition to stroke/SSE, better than the
HAS-BLED. Our study also confirms the previous literature in showing that statistical predictions are in
any case sub-optimal, in the light of the moderately good C-statistic. The risk of stroke/SSE and major
bleeding in our study population is slightly higher than in other publications studying the PREFER in
AF registry (see references listed in Table S5). This is likely due to the higher risk of the population
included and perhaps also because of the compression of risk of stroke and major bleeding observed
with the introduction of the NOACs. Our study, in particular, highlights the different weight of the
individual components of both scores to predict future death: here, the hierarchy of predictive weight
included congestive heart failure, hypertension, age>75 years, and diabetes among the CHA2DS2-VASc
components; whereas hypertension, liver function and age >65 years were the strongest predictors of
mortality in the HAS-BLED risk score. The different weight of individual components in risk prediction
for various outcomes is evidently diluted when attributing similar weights (1 or 2 points at best)
to the individual components. The usefulness of pursuing a better statistical prediction in spite of
reduced practicality—the main advantage of these easy-to-use scores—remains, however, debatable.
A novelty here, however, is that the combination of non-duplicated components of the two scores
had the highest predictive power for mortality, confirming on the one hand that both ischemic and
bleeding events can predict—and in part trigger—the frequent occurrence of death in anticoagulated
AF; but also that such components predict triggers of death not easily attributed to thromboembolism
or bleeding. The ability to predict such occurrences may allow the focusing on treatment of modifiable
risk factors, in addition to only focusing on thrombosis and bleeding, in such populations. Because of
the widespread use of the CHA2DS2-VASc and of the HAS-BLED risk score, a combination of their
individual components—as shown here—might be useful to risk-stratify patients in epidemiological
surveys and prospective trials, as well as, possibly, to better allocate incremental preventive measures.
5. Limitations
Although recruitment of consecutive patients at each center was mandatory in PREFER in AF,
we cannot exclude biases in patient enrollment and selection, as well as in treatment decisions.
Patients excluded from the study sample were fairly numerous; therefore, a limitation is the relatively
frequent lack of reporting of risk scores/missing values in the overall registry. Overall, mean age of the
study sample was slightly older than in the non-study sample, but the different distribution of other
factors (more use of VKA and higher prevalence of CKD) suggests that patient cases included were
perhaps more severe than patients excluded. Such considerations limit, in any case, the generalizability
of the findings to the unselected PREFER in AF population. Moreover, mortality data could not
exactly reflect real mortality, because data were extracted from the comments section of the electronic
case-report forms, making death reporting potentially less accurate. However, we estimated that
errors in this largely undisputed outcome are unlikely to be numerically relevant. The investigators’
diligence on reporting adverse events was here indeed crucial for the accuracy of data collection.
As for model analyses, there were a couple of limitations when evaluating predictive ability using
discrimination and calibration measures. Our study was aimed at mainly investigating the predictive
power of the CHA2DS2-VASc and HAS-BLED risk scores, as well as their combination, on mortality,
especially compared to the separate risk scores, therefore no re-calibration of coefficients was conducted.
We also deliberately did not venture in analyzing causes of death, likely unprecise and not sufficiently
controlled in the registry. The relative shortness of the study follow-up is a further limit with a
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focus on mortality, but data presented here are the first focusing on this endpoint in anticoagulated
patients in attempts at improving prediction with a combination of the two most widely used scores.
Finally, at the time of the PREFER in AF registry, most patients with AF were treated with VKAs,
which does not reflect the current prevalent treatment with NOACs. Whether such limitations affect
current applicability of our findings is likely minor, considering the lack of a biologic plausibility
(we do not suspect differences in risk prediction once adequate anticoagulation is ensured), and the
reassuring results of our sensitivity analyses. The usefulness of the newly proposed combination score
should be now, however, further tested in independent cohorts.
6. Conclusions
Mortality is an important component, so far insufficiently underscored, of the risk connected with
AF. The CHA2DS2-VASc and the HAS-BLED scores both predict mortality in AF, and a combination
of all their components increases prediction significantly. Such combination may be clinically useful.
Until now, the main focus of research in AF has been stroke/SSE and bleeding. The availability of
robust, real-world data to inform on patients’ risk of death, now numerically more relevant than
stroke/SEE in well-anticoagulated patients, will help to better identify strategies to further improve on
AF outcomes.
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Abbreviations
AF Atrial fibrillation
ATRIA AnTicoagulation and Risk factors In Atrial fibrillation
AUC Area under the curve
CHADS2 Congestive heart failure, hypertension, age ≥ 75 years, diabetes, stroke/transient
ischemic attack/thromboembolism [doubled]
CHA2DS2-VASc Congestive heart failure, hypertension, age ≥ 75 years [doubled], diabetes,
stroke/transient ischemic attack/thromboembolism [doubled], vascular disease [prior
myocardial infarction, peripheral artery disease, or aortic plaque], age 65–75 years, sex
category [female]
CRUSADE Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes
with Early implementation of the ACC/AHA guidelines
DACH Germany (Deutschland), Austria, Switzerland (Confederatio Helvetica)
eCRF Electronic case report form
GOF Hosmer and Lemeshow goodness-of-fit test
GRACE Global Registry of Acute Coronary Events
HAS-BLED hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition,
labile international normalized ratio [INR], elderly [age ≥ 65 years], drugs/alcohol
concomitantly
IDI Integrated discrimination improvement
ISTH International Society on Thrombosis and Haemostasis
NRI Net reclassification improvement
NOAC non-vitamin K antagonist oral anticoagulant
PREFER in AF Prevention of Thromboembolic Events—European Registry in Atrial Fibrillation” study
SD Standard deviation of the mean
SEE Systemic embolic event
TIA Transient ischemic attack
TIMI Thrombolysis In Myocardial Infarction
VKA Vitamin K antagonist
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